0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In locally advanced rectal cancer, radiotherapy (RT) followed by surgery have improved locoregional control, but distant recurrences remain frequent. Although checkpoint inhibitors have demonstrated objective response in several cancers, the clinical benefit of PD-1/PD-L1 blockade remains uncertain in rectal cancer. We collected data from biopsies and surgical specimens in 74 patients. The main objective was to evaluate the impact of neoadjuvant RT and fractionation on PD-L1 expression. Secondary objectives were to study the relation between PD-L1 expression and tumor regression grade (TRG), progression-free survival (PFS), overall survival (OS), and CD8 TILs infiltration. Median rates of cells expressing PD-L1 pre- and post-RT were 0.15 (range, 0–17) and 0.5 (range, 0–27.5), respectively ( p = 0.0005). There was no effect of RT fractionation on PD-L1+ cell rates. We found no relation between CD8+ TILs infiltration and PD-L1 expression and no difference between high-PD-L1 or low-PD-L1 expression and TRG. High-to-high PD-L1 expression profile had none significant higher OS and PFS compared to all other groups ( p = 0.06). Median OS and PFS were higher in biopsies with >0.08 PD-L1+ cells. High-to-high PD-L1 profile and ypT0-2 were significantly associated with higher OS and PFS. This study did not show the differential induction of PD-L1 expression according to fractionation.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

          Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            QuPath: Open source software for digital pathology image analysis

            QuPath is new bioimage analysis software designed to meet the growing need for a user-friendly, extensible, open-source solution for digital pathology and whole slide image analysis. In addition to offering a comprehensive panel of tumor identification and high-throughput biomarker evaluation tools, QuPath provides researchers with powerful batch-processing and scripting functionality, and an extensible platform with which to develop and share new algorithms to analyze complex tissue images. Furthermore, QuPath’s flexible design makes it suitable for a wide range of additional image analysis applications across biomedical research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

              The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.
                Bookmark

                Author and article information

                Journal
                Cells
                Cells
                cells
                Cells
                MDPI
                2073-4409
                10 September 2020
                September 2020
                : 9
                : 9
                : 2071
                Affiliations
                [1 ]Department of Radiation Oncology, Unicancer—Georges-Francois Leclerc Cancer Center, 21079 Dijon, France; jboustani@ 123456cgfl.fr (J.B.); vmorgand@ 123456cgfl.fr (V.M.)
                [2 ]Immunomolecular Therapies in Cancer (TIMC), INSERM UMR1098, 25000 Besancon, France; olivier.adotevi@ 123456univ-fcomte.fr
                [3 ]Cancer Biology Research Platform, Unicancer—Georges-Francois Leclerc Cancer Center, 21079 Dijon, France; vderangere@ 123456cgfl.fr (V.D.); fghiringhelli@ 123456cgfl.fr (F.G.)
                [4 ]INSERM UMR 1231, 21079 Dijon, France
                [5 ]Methodology, Data-Management and Biostatistics Unit, Unicancer—Center Georges-Francois Leclerc, 21079 Dijon, France; abertaut@ 123456cgfl.fr
                [6 ]Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France
                [7 ]Department of Pathology, Unicancer—Georges-Francois Leclerc Cancer Center, 21079 Dijon, France; ccharonbarra@ 123456cgfl.fr
                Author notes
                [* ]Correspondence: cmirjolet@ 123456cgfl.fr ; Tel.: +33-(0)3-45-34-80-75; Fax: +33-(0)3-80-73-77-06
                Author information
                https://orcid.org/0000-0002-7934-9509
                https://orcid.org/0000-0002-5465-8305
                https://orcid.org/0000-0003-0047-9421
                Article
                cells-09-02071
                10.3390/cells9092071
                7563314
                32927784
                c4893d71-05b0-4216-a705-7ec4ae110c36
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 28 July 2020
                : 07 September 2020
                Categories
                Article

                rectal cancer,neoadjuvant radiotherapy,fractionation,pd-l1 expression

                Comments

                Comment on this article